MediciNova announced that the Investigational New Drug Application (IND) for MN-166 for treatment of glioblastoma has been accepted and is now open with the U.S. Food and Drug Administration. MediciNova was informed by the FDA that the proposed clinical investigation of MN-166 in combination with temozolomide for treatment of GBM may proceed. “We are very pleased that this important regulatory step is now completed, as we can now pursue clinical development of MN-166 in GBM, a devastating type of cancer with a high recurrence rate and very poor prognosis. As we previously reported, combination treatment of MN-166 (ibudilast) and TMZ improved survival compared to TMZ-only treatment in a GBM animal model study,” commented Yuichi Iwaki, MediciNova CEO.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.